|
The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer |
Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retel VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R, Dubsky P |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retel VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R, Dubsky P. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer. British Journal of Cancer 2014; 111(5): 837-842 Indexing Status Subject indexing assigned by NLM MeSH Breast Neoplasms /diagnosis /genetics; Cost-Benefit Analysis /methods; Female; Gene Expression Profiling /methods; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2 /genetics; Receptors, Estrogen /genetics; Risk; Transcriptome /genetics AccessionNumber 22014035946 Date bibliographic record published 20/11/2014 |
|
|
|